Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00049972 |
A study to obtain safety and tolerability data
Condition | Intervention | Phase |
---|---|---|
Major Depressive Disorder |
Drug: paroxetine CR |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Safety Study |
Official Title: | An Open Label Study Assessing Paxil CR (Paroxetine CR) in Patients With Major Depressive Disorder Who Discontinued Treatment With Selective Serotonin Reuptake Inhibitors or a Selective Serotonin/Norepinephrine Reuptake Inhibitor Due to Intolerability |
Estimated Enrollment: | 646 |
Study Start Date: | September 2002 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Chair: | GSK Clinical Trials, MD | GlaxoSmithKline |
Study ID Numbers: | SB29060.833 |
Study First Received: | November 18, 2002 |
Last Updated: | January 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00049972 |
Health Authority: | United States: Food and Drug Administration |
Major Depressive Disorder
Open-label
discontinued |
Depression Mental Disorders Norepinephrine Mood Disorders Depressive Disorder, Major |
Depressive Disorder Paroxetine Serotonin Behavioral Symptoms |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors |
Pharmacologic Actions Pathologic Processes Serotonin Agents Therapeutic Uses Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |